40,500 Australian infants unprotected from RSV — a postcode lottery

What just happened

Australia’s RSV Mother and Infant Protection Program has a structural problem that is now visible in the numbers. From January to August 2026, 159,000 Australian infants received RSV protection — but approximately 40,500 did not. The Immunisation Foundation of Australia estimates this gap has translated to roughly 1,620 preventable hospitalisations.

RSV — respiratory syncytial virus — is the single most common reason for infant hospitalisation in Australia. In young infants, particularly those under three months, RSV infection can progress rapidly to bronchiolitis requiring oxygen, intensive monitoring, or intensive care. The illness is not rare, it is not mild in this age group, and it is preventable with the tools that now exist.

The program that was designed to prevent it is delivering those tools very unevenly depending on which state a baby is born in.

Both-and

How a national program became a postcode lottery

RSV-MIPP was launched in 2025 with an architecture that split along funding lines: maternal RSV vaccination funded nationally, infant RSV antibody prophylaxis funded state by state. The logic behind the split was practical — federal-state cost-sharing in immunisation programs is not new — but the consequence is a program that functions differently depending on where a family lives.

WA and QLD delivered 60% of all infant antibody immunisations in 2026, despite representing only 30% of Australian births. NSW and VIC combined delivered just one-third of doses. Those two states account for the majority of Australia’s birth cohort. The states with the most infants are the states delivering the least coverage.

This is not a theoretical inequity. It is a measurable difference in the number of infants protected, and by extension the number hospitalised.

The provider experience mirrors the patient experience

The inequity is not only experienced by families. GPs, midwives, and immunisation providers are operating in a landscape that Catherine Hughes, director of the Immunisation Foundation of Australia, described as “wrapped in a complex web of varying eligibility rules that confuse providers and families.” Dr Rochelle Oei-Hicks noted directly that the state divide is impacting health outcomes.

A GP in Queensland advising a pregnant patient about RSV protection for her newborn gives a different practical answer than a GP in New South Wales. Both are telling the truth about what is available in their jurisdiction. The patchwork is the problem — not the providers navigating it.

There are also eligibility variation issues within states, not just between them. Some state programs include additional criteria beyond the national maternal vaccination program — gestational age thresholds, risk-factor criteria, catch-up windows — that vary enough to create confusion even for providers who are actively trying to give correct advice. A program that requires a clinician to verify which state they are in before advising a patient about a nationally promoted infant protection strategy is not operating at its intended efficiency.

What the IFA is calling for

The Immunisation Foundation of Australia has called for infant RSV antibody prophylaxis to be added to the National Immunisation Program with uniform national eligibility, universal maternal vaccination from 28 weeks gestation standardised nationwide, and consistent information for both providers and families across all jurisdictions.

The NIP pathway would remove the state-funding variation by making infant RSV prophylaxis a Commonwealth-funded entitlement for all infants, regardless of which state they are born in — the same model that governs funded vaccines for meningococcal B, rotavirus, and influenza in eligible age groups.

This is a policy ask, not a clinical announcement. The decision rests with the Australian Technical Advisory Group on Immunisation and the federal health department. But the data the IFA has presented — 40,500 unprotected infants, 1,620 preventable hospitalisations in eight months — is the kind of number that moves policy conversations.

2 cents

For GPs who are seeing pregnant patients: know what your state program currently covers for infant RSV antibody protection. Maternal RSV vaccination is nationally funded and can be offered consistently. Infant antibody prophylaxis availability after birth is where the state variation sits, and giving a family accurate expectations about what they can access at their local hospital or maternal and child health service avoids the downstream confusion of being told the protection is not available.

For families who have been told their infant is not eligible for RSV antibody protection in their state: maternal vaccination during pregnancy still provides meaningful antibody transfer to the newborn. It is not the same as direct infant prophylaxis but it is not nothing. The protective effect is real.

The argument for NIP listing of infant RSV prophylaxis has been building since the program launched. The 2026 coverage data gives it quantified weight. Whether the federal government acts in the next funding round is the question.

This is general information. For advice on a specific pregnancy or infant’s RSV protection options, a GP or maternal and child health nurse is the right place to start.

Verdict: yes — worth knowing about. 40,500 unprotected infants in eight months from a preventable illness is a policy failure with clinical consequences. The postcode lottery is real.

---

Sources cited

1. Call to address ‘chaotic and confusing’ RSV vaccination approach. RACGP newsGP, 10 September 2026.